Calithera Biosciences (NASDAQ:CALA – Get Free Report) will likely be releasing its resultson Tuesday, August 18th. Analysts expect Calithera Biosciences to post earnings of ($5.5188) per share and revenue of $0.48 million for the quarter.
Calithera Biosciences Stock Down 100.0%
Calithera Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies.
The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity.
Further Reading
- Five stocks we like better than Calithera Biosciences
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
